: The research tracks how certain mutations (like the L398P variant) affect the protein's breakdown when exposed to ATRA/Arsenic Trioxide (ATO) combination treatments.
: It examines the ability of the mutant proteins to exchange nuclear co-repressors for co-activators, which is a critical factor in how the body responds—or fails to respond—to therapy. 24010.rar
Mutations : The study focuses on mutations localized to the RAR : The research tracks how certain mutations (like
